Vanguard Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $41.3B | Buy |
180,779,699
+3,032,438
| +2% | +$691M | 0.6% | 18 |
|
|
2025
Q3 | $41.2B | Buy |
177,747,261
+448,554
| +0.3% | +$91.3M | 0.62% | 20 |
|
|
2025
Q2 | $32.9B | Buy |
177,298,707
+3,380,842
| +2% | +$628M | 0.53% | 23 |
|
|
2025
Q1 | $36.4B | Buy |
173,917,865
+845,787
| +0.5% | +$164M | 0.66% | 21 |
|
|
2024
Q4 | $30.8B | Buy |
173,072,078
+1,424,237
| +0.8% | +$262M | 0.54% | 23 |
|
|
2024
Q3 | $33.9B | Buy |
171,647,841
+988,295
| +0.6% | +$184M | 0.61% | 22 |
|
|
2024
Q2 | $29.3B | Buy |
170,659,546
+282,800
| +0.2% | +$46.8M | 0.56% | 22 |
|
|
2024
Q1 | $31B | Buy |
170,376,746
+9,978,415
| +6% | +$1.72B | 0.61% | 21 |
|
|
2023
Q4 | $24.9B | Sell |
160,398,331
-349,024
| -0.2% | -$50.9M | 0.54% | 22 |
|
|
2023
Q3 | $24B | Buy |
160,747,355
+1,450,089
| +0.9% | +$213M | 0.59% | 22 |
|
|
2023
Q2 | $21.5B | Sell |
159,297,266
-1,169,081
| -0.7% | -$171M | 0.51% | 24 |
|
|
2023
Q1 | $25.6B | Buy |
160,466,347
+2,148,795
| +1% | +$329M | 0.65% | 21 |
|
|
2022
Q4 | $25.6B | Buy |
158,317,552
+2,295,138
| +1% | +$352M | 0.7% | 20 |
|
|
2022
Q3 | $20.9B | Buy |
156,022,414
+2,442,663
| +2% | +$351M | 0.62% | 22 |
|
|
2022
Q2 | $23.5B | Buy |
153,579,751
+3,060,971
| +2% | +$468M | 0.66% | 20 |
|
|
2022
Q1 | $24.4B | Buy |
150,518,780
+4,206,711
| +3% | +$611M | 0.58% | 20 |
|
|
2021
Q4 | $19.8B | Buy |
146,312,069
+782,554
| +0.5% | +$92.4M | 0.45% | 32 |
|
|
2021
Q3 | $15.7B | Buy |
145,529,515
+835,949
| +0.6% | +$95.5M | 0.39% | 42 |
|
|
2021
Q2 | $16.3B | Buy |
144,693,566
+959,620
| +0.7% | +$108M | 0.41% | 37 |
|
|
2021
Q1 | $15.6B | Buy |
143,733,946
+1,170,872
| +0.8% | +$125M | 0.42% | 37 |
|
|
2020
Q4 | $15.3B | Sell |
142,563,074
-1,771,776
| -1% | -$170M | 0.44% | 34 |
|
|
2020
Q3 | $12.6B | Sell |
144,334,850
-3,051,958
| -2% | -$287M | 0.42% | 40 |
|
|
2020
Q2 | $14.5B | Buy |
147,386,808
+21,786,239
| +17% | +$1.92B | 0.51% | 32 |
|
|
2020
Q1 | $9.57B | Buy |
125,600,569
+3,025,849
| +2% | +$258M | 0.41% | 43 |
|
|
2019
Q4 | $10.9B | Buy |
122,574,720
+811,900
| +0.7% | +$67.4M | 0.37% | 46 |
|
|
2019
Q3 | $9.22B | Buy |
121,762,820
+239,282
| +0.2% | +$16.4M | 0.34% | 50 |
|
|
2019
Q2 | $8.84B | Buy |
121,523,538
+679,398
| +0.6% | +$53.4M | 0.33% | 55 |
|
|
2019
Q1 | $9.74B | Buy |
120,844,140
+260,715
| +0.2% | +$21.3M | 0.38% | 43 |
|
|
2018
Q4 | $11.1B | Buy |
120,583,425
+1,821,118
| +2% | +$160M | 0.5% | 32 |
|
|
2018
Q3 | $11.2B | Buy |
118,762,307
+912,625
| +0.8% | +$86.5M | 0.44% | 35 |
|
|
2018
Q2 | $10.9B | Sell |
117,849,682
-3,611,083
| -3% | -$353M | 0.46% | 32 |
|
|
2018
Q1 | $11.5B | Buy |
121,460,765
+1,608,203
| +1% | +$177M | 0.5% | 29 |
|
|
2017
Q4 | $11.6B | Buy |
119,852,562
+1,905,909
| +2% | +$180M | 0.51% | 30 |
|
|
2017
Q3 | $10.5B | Buy |
117,946,653
+2,025,980
| +2% | +$154M | 0.49% | 31 |
|
|
2017
Q2 | $8.41B | Buy |
115,920,673
+3,706,941
| +3% | +$249M | 0.41% | 38 |
|
|
2017
Q1 | $7.31B | Buy |
112,213,732
+2,676,969
| +2% | +$168M | 0.38% | 40 |
|
|
2016
Q4 | $6.86B | Buy |
109,536,763
+2,129,277
| +2% | +$130M | 0.38% | 41 |
|
|
2016
Q3 | $6.77B | Buy |
107,407,486
+3,324,478
| +3% | +$215M | 0.4% | 41 |
|
|
2016
Q2 | $6.44B | Buy |
104,083,008
+998,196
| +1% | +$60.8M | 0.4% | 44 |
|
|
2016
Q1 | $5.89B | Buy |
103,084,812
+3,465,191
| +3% | +$193M | 0.38% | 44 |
|
|
2015
Q4 | $5.9B | Buy |
99,619,621
+394,666
| +0.4% | +$22.7M | 0.4% | 44 |
|
|
2015
Q3 | $5.4B | Sell |
99,224,955
-1,785,344
| -2% | -$116M | 0.39% | 44 |
|
|
2015
Q2 | $6.79B | Buy |
101,010,299
+8,592,962
| +9% | +$561M | 0.46% | 35 |
|
|
2015
Q1 | $5.41B | Buy |
92,417,337
+3,573,940
| +4% | +$216M | 0.37% | 47 |
|
|
2014
Q4 | $5.81B | Buy |
88,843,397
+2,892,424
| +3% | +$182M | 0.42% | 39 |
|
|
2014
Q3 | $4.96B | Buy |
85,950,973
+232,664
| +0.3% | +$12.9M | 0.39% | 42 |
|
|
2014
Q2 | $4.84B | Buy |
85,718,309
+1,455,874
| +2% | +$76.4M | 0.38% | 42 |
|
|
2014
Q1 | $4.33B | Buy |
84,262,435
+1,986,210
| +2% | +$100M | 0.36% | 45 |
|
|
2013
Q4 | $4.35B | Buy |
82,276,225
+1,696,130
| +2% | +$83.4M | 0.38% | 43 |
|
|
2013
Q3 | $3.6B | Buy |
80,580,095
+3,060,527
| +4% | +$136M | 0.35% | 43 |
|
|
2013
Q2 | $3.2B | Buy |
+77,519,568
| New | +$3.39B | 0.34% | 47 |
|
Other funds holding ABBV
Vanguard Group's ABBV Position: Q4 2025 in Review
Vanguard Group increased its AbbVie (ABBV) stake by 1.7% in Q4 2025, buying an estimated $691M and bringing the position to 180,779,699 shares worth $41.3B. The position accounts for 0.6% of the portfolio, ranked #18.
Vanguard Group first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.
- Vanguard Group held 180,779,699 shares of AbbVie worth $41.3B as of Q4 2025.
- Vanguard Group bought 3,032,438 AbbVie shares in Q4 2025, an estimated $691M.
- AbbVie made up 0.6% of Vanguard Group's portfolio in Q4 2025, its #18 holding.
- Vanguard Group first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
- 4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.